12:00 AM
 | 
Jan 25, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Cimzia certolizumab pegol regulatory update

The U.K.'s NICE issued a final appraisal determination recommending Cimzia certolizumab pegol from UCB Group to treat rheumatoid arthritis only if UCB provides the first 12 weeks of treatment for free to all patients...

Read the full 150 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >